EPHA10 (EPH receptor A10) is a receptor tyrosine kinase that binds ephrin-A ligands (EFNA3, EFNA4, EFNA5) and functions in ephrin receptor signaling 1. Originally identified as testis-expressed, EPHA10 is remarkably overexpressed in multiple cancers including breast, prostate, lung adenocarcinoma, and ovarian cancers, while remaining absent from most normal tissues 234. In breast cancer, EPHA10 coexpression with Gli3 promotes cell proliferation, invasion, and migration 5, and its expression correlates with poor prognosis across cancer subtypes including triple-negative breast cancer 6. Mechanistically, EPHA10 activates the MAPK/ERK cascade to drive tumor progression and upregulates PD-L1 to mediate immune evasion 4. The cancer-specific expression profile makes EPHA10 an attractive therapeutic target; anti-EPHA10 monoclonal antibodies and antibody-drug conjugates (EPHA10-MMAE) demonstrate significant cytotoxic effects against cancer cells, including those resistant to established therapies 36. EPHA10-specific CAR-T cell therapy shows promise in preclinical models 6. Additionally, EPHA10 is implicated in autosomal dominant deafness-88, though mechanism details are insufficient from provided abstracts.